Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Challenges with stopping long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

Liem KS, Gehring AJ, Feld JJ, Janssen HLA.

Gastroenterology. 2019 Dec 3. pii: S0016-5085(19)41872-6. doi: 10.1053/j.gastro.2019.10.050. [Epub ahead of print] No abstract available.

PMID:
31809724
2.

A global scientific strategy to cure hepatitis B.

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e7.

3.

Host-pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs.

Feld JJ, Gehring AJ.

Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):77-78. doi: 10.1038/s41575-018-0101-y. Review. No abstract available.

PMID:
30617296
4.

Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection.

Gehring AJ, Protzer U.

Gastroenterology. 2019 Jan;156(2):325-337. doi: 10.1053/j.gastro.2018.10.032. Epub 2018 Oct 24. Review.

PMID:
30367834
5.

New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies.

Gehring AJ.

Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):337-345. doi: 10.1016/j.bpg.2017.05.004. Epub 2017 May 25. Review.

PMID:
28774416
6.

Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.

Ghazarian M, Revelo XS, Nøhr MK, Luck H, Zeng K, Lei H, Tsai S, Schroer SA, Park YJ, Chng MHY, Shen L, D'Angelo JA, Horton P, Chapman WC, Brockmeier D, Woo M, Engleman EG, Adeyi O, Hirano N, Jin T, Gehring AJ, Winer S, Winer DA.

Sci Immunol. 2017 Apr 21;2(10). pii: eaai7616. doi: 10.1126/sciimmunol.aai7616.

7.

The role of innate immunity in the immunopathology and treatment of HBV infection.

Maini MK, Gehring AJ.

J Hepatol. 2016 Apr;64(1 Suppl):S60-S70. doi: 10.1016/j.jhep.2016.01.028. Review.

PMID:
27084038
8.

Trained immunity in newborn infants of HBV-infected mothers.

Hong M, Sandalova E, Low D, Gehring AJ, Fieni S, Amadei B, Urbani S, Chong YS, Guccione E, Bertoletti A.

Nat Commun. 2015 Mar 25;6:6588. doi: 10.1038/ncomms7588.

9.

Reply to: "To target or not to target viral antigens in HBV related HCC?".

Qasim W, Brunetto M, Gehring AJ, Maini MK, Bonino F, Stauss H, Bertoletti A.

J Hepatol. 2015 Jun;62(6):1450-2. doi: 10.1016/j.jhep.2015.02.026. Epub 2015 Feb 21. No abstract available.

10.

Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.

Gehring AJ, Ann D'Angelo J.

Cell Mol Immunol. 2015 May;12(3):283-91. doi: 10.1038/cmi.2014.95. Epub 2014 Nov 3. Review.

11.

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.

Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini MK, Bonino F, Stauss H, Bertoletti A.

J Hepatol. 2015 Feb;62(2):486-91. doi: 10.1016/j.jhep.2014.10.001. Epub 2014 Oct 13.

PMID:
25308176
12.

A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee YJ, Kottilil S, Bellgrau D, Rodell T, Apelian D.

PLoS One. 2014 Jul 22;9(7):e101904. doi: 10.1371/journal.pone.0101904. eCollection 2014.

13.

Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver.

Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A, To N, Hong M, Chia A, Gill US, Kennedy PT, Tan KC, Lee KH, De Libero G, Gehring AJ, Willberg CB, Klenerman P, Bertoletti A.

PLoS Pathog. 2014 Jun 26;10(6):e1004210. doi: 10.1371/journal.ppat.1004210. eCollection 2014 Jun.

14.

Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections.

Banu N, Chia A, Ho ZZ, Garcia AT, Paravasivam K, Grotenbreg GM, Bertoletti A, Gehring AJ.

Sci Rep. 2014 Feb 25;4:4166. doi: 10.1038/srep04166.

15.

Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?

Bertoletti A, Gehring AJ.

PLoS Pathog. 2013;9(12):e1003784. doi: 10.1371/journal.ppat.1003784. Epub 2013 Dec 19. No abstract available.

16.

How further suppression of virus replication could improve current HBV treatment.

Tavis JE, Gehring AJ, Hu Y.

Expert Rev Anti Infect Ther. 2013 Aug;11(8):755-7. doi: 10.1586/14787210.2013.814846. No abstract available.

17.

A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus.

Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A.

Mol Ther Nucleic Acids. 2013 Aug 13;2:e114. doi: 10.1038/mtna.2013.43.

18.

Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A, Banu N, Chia A, Lim SG, Ferrari C, Ginhoux F, Bertoletti A.

J Clin Invest. 2013 Sep;123(9):3766-76. doi: 10.1172/JCI66043. Epub 2013 Aug 1.

19.

IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells.

Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, Lee KH, Gehring AJ, De Libero G, Bertoletti A.

J Immunol. 2013 Apr 1;190(7):3142-52. doi: 10.4049/jimmunol.1203218. Epub 2013 Feb 27.

20.

Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases.

Chang CX, Tan AT, Or MY, Toh KY, Lim PY, Chia AS, Froesig TM, Nadua KD, Oh HL, Leong HN, Hadrup SR, Gehring AJ, Tan YJ, Bertoletti A, Grotenbreg GM.

Eur J Immunol. 2013 Apr;43(4):1109-20. doi: 10.1002/eji.201243088. Epub 2013 Feb 14.

21.

Binding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes.

Low JL, Naidoo A, Yeo G, Gehring AJ, Ho ZZ, Yau YH, Shochat SG, Kranz DM, Bertoletti A, Grotenbreg GM.

PLoS One. 2012;7(12):e51397. doi: 10.1371/journal.pone.0051397. Epub 2012 Dec 10.

22.

Licensing virus-specific T cells to secrete the neutrophil attracting chemokine CXCL-8 during hepatitis B virus infection.

Gehring AJ, Koh S, Chia A, Paramasivam K, Chew VS, Ho ZZ, Lee KH, Maini MK, Madhavan K, Lim SG, Bertoletti A.

PLoS One. 2011;6(8):e23330. doi: 10.1371/journal.pone.0023330. Epub 2011 Aug 18.

23.

Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.

Oh HL, Chia A, Chang CX, Leong HN, Ling KL, Grotenbreg GM, Gehring AJ, Tan YJ, Bertoletti A.

J Virol. 2011 Oct;85(20):10464-71. doi: 10.1128/JVI.05039-11. Epub 2011 Aug 3.

24.

Stability screening of arrays of major histocompatibility complexes on combinatorially encoded flow cytometry beads.

Chew SL, Or MY, Chang CX, Gehring AJ, Bertoletti A, Grotenbreg GM.

J Biol Chem. 2011 Aug 12;286(32):28466-75. doi: 10.1074/jbc.M111.262691. Epub 2011 Jun 16.

25.

Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody.

Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L, Kennedy PT, Lopatin U, Macary PA, Bertoletti A.

J Virol. 2011 Mar;85(5):1935-42. doi: 10.1128/JVI.01990-10. Epub 2010 Dec 15.

26.

Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.

Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A.

J Hepatol. 2011 Jul;55(1):103-10. doi: 10.1016/j.jhep.2010.10.025. Epub 2010 Nov 23.

PMID:
21145860
27.

A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B.

Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG, Bertoletti A.

J Hepatol. 2010 Mar;52(3):330-9. doi: 10.1016/j.jhep.2009.12.015. Epub 2010 Jan 13.

PMID:
20137825
28.

HBV-Specific Adaptive Immunity.

Bertoletti A, Tan AT, Gehring AJ.

Viruses. 2009 Sep;1(2):91-103. doi: 10.3390/v1020091. Epub 2009 Jul 27.

29.

Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.

Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A.

Gastroenterology. 2009 Aug;137(2):682-90. doi: 10.1053/j.gastro.2009.04.045. Epub 2009 Apr 23.

PMID:
19394336
30.

The expression and function of NKG2D molecule on intrahepatic CD8+ T cells in chronic viral hepatitis.

Kennedy PT, Gehring AJ, Nowbath A, Selden C, Quaglia A, Dhillon A, Dusheiko G, Bertoletti A.

J Viral Hepat. 2008 Dec;15(12):901-9. doi: 10.1111/j.1365-2893.2008.01049.x.

PMID:
19087227
31.

Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire.

Tan AT, Loggi E, Boni C, Chia A, Gehring AJ, Sastry KS, Goh V, Fisicaro P, Andreone P, Brander C, Lim SG, Ferrari C, Bihl F, Bertoletti A.

J Virol. 2008 Nov;82(22):10986-97. doi: 10.1128/JVI.01124-08. Epub 2008 Sep 17.

32.

The level of viral antigen presented by hepatocytes influences CD8 T-cell function.

Gehring AJ, Sun D, Kennedy PT, Nolte-'t Hoen E, Lim SG, Wasser S, Selden C, Maini MK, Davis DM, Nassal M, Bertoletti A.

J Virol. 2007 Mar;81(6):2940-9. Epub 2007 Jan 3.

33.

Phosphatidylinositol mannoside from Mycobacterium tuberculosis binds alpha5beta1 integrin (VLA-5) on CD4+ T cells and induces adhesion to fibronectin.

Rojas RE, Thomas JJ, Gehring AJ, Hill PJ, Belisle JT, Harding CV, Boom WH.

J Immunol. 2006 Sep 1;177(5):2959-68.

34.

Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function.

Pecora ND, Gehring AJ, Canaday DH, Boom WH, Harding CV.

J Immunol. 2006 Jul 1;177(1):422-9.

35.

The immune response during hepatitis B virus infection.

Bertoletti A, Gehring AJ.

J Gen Virol. 2006 Jun;87(Pt 6):1439-49. Review.

PMID:
16690908
36.

Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection.

Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, Bertoletti A.

J Virol. 2005 Mar;79(6):3322-8.

37.

Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing.

Gehring AJ, Dobos KM, Belisle JT, Harding CV, Boom WH.

J Immunol. 2004 Aug 15;173(4):2660-8.

38.
39.

Human immunity to M. tuberculosis: T cell subsets and antigen processing.

Boom WH, Canaday DH, Fulton SA, Gehring AJ, Rojas RE, Torres M.

Tuberculosis (Edinb). 2003;83(1-3):98-106. Review.

PMID:
12758197

Supplemental Content

Loading ...
Support Center